Abacavir
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Abacavir
- Pharmacist Assessment Report
- Abacavir: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Abacavir: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Abacavir was originally used to treat HIV infection and AIDS. The TxGNN model predicts it may be effective for feline acquired immunodeficiency syndrome (FIV infection), but there are currently no clinical trials and only 1 publication (a preclinical combination-therapy study), so the evidence is very limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV infectious disease; AIDS |
| Predicted New Indication | Feline acquired immunodeficiency syndrome |
| TxGNN Prediction Score | 0.9979 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 8 of 9; dormant: 1) |
| Number of DINs | 9 (marketed: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI). Inside cells it is converted to carbovir triphosphate, which stops viral DNA chains from growing. Detailed mechanism of action data is not available in the data compiled for this report, so this description reflects general knowledge of the drug class.
Feline immunodeficiency virus (FIV) is a lentivirus whose reverse transcriptase is similar to that of HIV-1. This gives the prediction a plausible mechanistic basis. The original indication (HIV/AIDS) and the predicted one are essentially the same type of disease, caused by closely related viruses, and the cat is widely used as an animal model for HIV.
Two caveats apply. The only supporting study tested abacavir together with zidovudine and lamivudine, so abacavir’s own contribution cannot be separated. And because this is a veterinary indication, direct translation to human use is not applicable. The high score likely reflects similarity to the existing HIV indication more than independent evidence.
Two other predictions were also reviewed:
- Simian immunodeficiency virus infection (score 0.9979): supported only by a 2004 in vitro susceptibility study (PMID 15040537). It is mainly a research model for HIV and does not represent a distinct opportunity for humans.
- Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter (score 0.9978): no trials or literature, and no identified mechanistic link. It is a computational prediction only (evidence level L5).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11684314 | 2002 | Preclinical / animal study | Antiviral Research | Combined zidovudine, lamivudine and abacavir therapy suppressed FIV replication in vitro; FIV in cats is used as a model of HIV infection |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02240358 | ZIAGEN | Not specified | Not specified |
| 02480956 | MINT-ABACAVIR | Not specified | Not specified |
| 02396769 | APO-ABACAVIR | Not specified | Not specified |
| 02416662 | TEVA-ABACAVIR/LAMIVUDINE | Not specified | Not specified |
| 02450682 | MYLAN-ABACAVIR/LAMIVUDINE | Not specified | Not specified |
These are 5 of 9 valid authorizations in Canada; none is cancelled.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): liver failure, liver disease, fatty liver disease, non-alcoholic steatohepatitis, kidney disease, pancreatitis, gallbladder disease, lactic acidosis, neutropenia, agranulocytosis, anemia (including macrocytic anemia), hypertriglyceridemia, obesity disorders, myopathy and other muscle diseases (including myositis and dermatomyositis), familial periodic paralysis, and pyoureter.
- Drug Interactions: 93 interactions were identified. The ones with a stated severity are Naltrexone (Moderate) and Orlistat (Moderate). Others, such as metformin, morphine, omeprazole, pantoprazole, prednisone and vancomycin, have no severity classification.
- Genetic hypersensitivity risk: abacavir is associated with HLA-B*57:01 hypersensitivity, which is relevant to any new use in humans.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction is a veterinary indication supported by a single preclinical combination-therapy study, so abacavir’s own effect is not isolated and human translation does not apply. The SIV prediction rests on in vitro data only, and the neurodevelopmental disorder prediction has no supporting evidence and no mechanistic link.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data
- Abacavir-alone data (not in combination) for the predicted indications
- Dosage form and approved indication details for the Canadian licenses
- A clear definition of the target use (veterinary vs. human) before any further development
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.